20 August 2020
Release date 19 August 2020
CSL Limited today announced a reported net profit after tax of $2,103 million for the 12 months ended 30 June 2020, up 10%, or 17% on a constant currency (CC2) basis.
Mr Paul Perreault, CSL’s Chief Executive Officer and Managing Director said, “I am pleased to report an exceptional result against a backdrop of complex and unexpected challenges brought about by the COVID-19 pandemic.”
“Our largest franchise, the immunoglobulin portfolio performed extremely well, with PRIVIGEN® sales growing 20% and HIZENTRA® sales up 34% . Underpinning this growth has been continued high patient demand for chronic conditions such as Primary Immune Deficiency, increased utilisation in the treatment of Secondary Immune Deficiency, together with the expanded CIDP label claim for both products. CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is a debilitating neurological disorder. HIZENTRA® growth has been especially strong, partly driven by increased demand for home-based treatments during the current pandemic.”
“Albumin sales grew well in key markets with the planned exception of China, where we transitioned to our new direct distribution model. This transition has seen overall albumin sales decrease 36% , which is in line with guidance. The China transition is now complete and will improve CSL’s participation in the value chain as well as allowing us to now work directly with clinicians. The availability of albumin to patients has not been impacted and reported sales are expected to return to a more normalised level in FY21,” Mr Perreault said.
“HAEGARDA®, our therapy for patients with Hereditary Angioedema (HAE) and IDELVION®, our therapy for Haemophilia B patients, have been transformational products and the sales growth reflects this. HAEGARDA® sales grew by 12%2 and IDELVION® sales are up 25% ,” Mr Perreault added.
Mr Perreault said, “When Seqirus was formed five years ago we provided long term targets for the business, which at the time was making a loss. Today, I’m very pleased to report Seqirus has delivered on strategy and exceeded those targets. Seqirus’ earnings before interest and taxes grew more than 70% this year underpinned by sales of new and differentiated products – FLUCELVAX® and FLUAD® .”